CLINICAL TRANSLATION OF HYPERPOLARIZED 13C-UREA FOR CANCER MR MOLECULAR IMAGING
CLINICAL TRANSLATION OF HYPERPOLARIZED 13C-UREA FOR CANCER MR MOLECULAR IMAGING
批准号:
10116302
负责人:
John Kurhanewicz
金额:
$60.09万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-03-06 至 2024-02-29
关键词:
2,4-DinitrophenolAddressAdvanced Malignant NeoplasmAndrogensBiopsyCancer PatientChemistryClinicClinicalClinical DataClinical ManagementClinical ResearchClinical TrialsDataDevelopmentDiagnosisDiseaseDoseEndotoxinsEvaluationFeasibility StudiesFormulationFrequenciesFutureGlandGoalsHumanHypoxiaImageImaging DeviceImaging TechniquesIndividualIndolentIndustrializationIndustryInjectionsInvestigationMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of prostateMeasuresMetabolicMetabolismMethodsMolecularMonitorMotivationOperative Surgical ProceduresOutcomePatient imagingPatientsPerformancePerfusionPharmacy facilityPhase I Clinical TrialsPositioning AttributePre-Clinical ModelPreclinical TestingProceduresProcessProductionPyruvateQuality ControlRadiation therapyRadical ProstatectomyResolutionSafetySiteStandardizationSterilityTechniquesTestingTherapeuticTimeTransgenic OrganismsTranslatingTranslationsUreaadvanced diseaseanticancer researchbasecancer clinical trialcancer genomicscancer imagingclinical investigationclinical translationdeprivationdesignfirst-in-humanhigh resolution imaginghuman diseasehuman imagingimaging approachimaging modalityimaging studyimprovedindividual patientindustry partnerinstrumentationmeetingsmetabolic imagingmicrobialmolecular imagingnew technologynovelnovel imaging technologyperfusion imagingpersonalized approachpersonalized carepre-clinicalpreclinical studyproduct developmentprostate cancer modelreconstructionresearch studyresponsesafety and feasibilitystandard of caresuccesstemporal measurementtherapeutic developmenttherapy resistanttooltreatment responsetumor metabolism
中文摘要
项目总结/摘要
这种学术界与工业界的合作旨在为惠普开发和转化新的仪器和技术
单独使用13 C-尿素MR灌注成像以及与HP 13 C-丙酮酸盐联合使用,以支持未来的临床研究
癌症患者,促进更个性化的治疗选择和监测方法。的
该项目的最终产品将是新的dDNP Spinlab偏振器硬件和方法能够产生
用于首次人体灌注和组合灌注与代谢成像的无菌超极化化合物
通过对前列腺癌患者的初步调查。为了完成这个重要的项目,我们已经聚集了
惠普是一个在临床前和临床癌症研究方面拥有专业知识的杰出学术和工业团队,
无菌混合、HP MRI开发和工业产品开发,以:开发化学、试剂
溶解DNP的硬件和方法,用于单独生产无菌HP 13 C-尿素,然后在
与无菌HP 13 C-丙酮酸盐组合(Aim 1)。开发和实施新型快速容积13 C MR
HP 13 C-尿素、13 C-丙酮酸及其代谢物的连续动态成像的成像方法,
时间和空间分辨率(目标2)。FDA IND所需的临床前试验和SOP开发
提交(目标3)。确定首次人体联合HP 13 C-尿素和13 C-尿素的安全性和成像可行性。
前列腺癌患者的丙酮酸盐MR成像研究(目的4)。
这种学术-工业合作的临床动机是,前列腺癌的管理是严重的,
受当前可用的临床和影像学信息的限制,需要选择最合适的治疗方法
并评估对治疗的反应或治疗耐药性的发展。
超极化(HP)13 C MRI是一种范式转变的新MR分子成像技术,
检测、表征侵袭性和监测治疗的措施,以改善癌症临床试验
和个性化的病人护理。这个项目的科学前提是,随着第一阶段的成功,
在前列腺癌患者中进行HP 13 C-丙酮酸盐成像的临床试验,
临床偏光镜,以及证明HP 13 C尿素和丙酮酸盐潜在价值的强有力的临床前数据
为了推进癌症成像,现在是将这项新技术转化为临床并整合到
将其转化为当前最先进的成像方法。这种学术界与工业界的伙伴关系对于
将这种新的成像技术转化为临床竞技场,UCSF和通用电气(GE)正在
共同实现这一目标的独特优势。
虽然新的超极化成像工具和方法的发展和传播,在这个学术-
工业伙伴关系将首先应用于前列腺癌患者,它们将具有普遍适用性
治疗各种癌症和其他人类疾病。
英文摘要
PROJECT SUMMARY / ABSTRACT
This Academic-Industry partnership aims to develop and translate new instrumentation and techniques for HP
13C-urea MR perfusion imaging alone and in combination with HP 13C-pyruvate to enable future clinical studies
of patients with cancer, facilitating a more personalized approach to therapeutic selection and monitoring. The
end product of this project will be new dDNP Spinlab polarizer hardware and methods capable of producing
sterile, hyperpolarized compounds for first-in-man perfusion and combined perfusion and metabolic imaging
through initial prostate cancer patient investigations. To accomplish this important project, we have assembled
an exceptional academic and industrial team with expertise in pre-clinical and clinical cancer research, HP
sterile compounding, HP MRI development, and industry product development to: Develop chemistry, agent
hardware and methods of dissolution DNP for the production of sterile HP 13C-urea by itself and then in
combination with sterile HP 13C-pyruvate (Aim 1). Develop and implement novel rapid volumetric 13C MR
imaging methods for serial dynamic imaging of HP 13C-urea, 13C-pyruvate and its metabolites, with high
temporal and spatial resolution (Aim 2). Preclinical Testing and SOP development required for FDA IND
submission (Aim 3). Establish safety and imaging feasibility of first-in-man combined HP 13C-urea and 13C-
pyruvate MR imaging studies in patients with prostate cancer (Aim 4).
The clinical motivation for this academic-industry partnership is that prostate cancer management is severely
limited by currently available clinical and imaging information required to select the most appropriate treatment
for individual patients and to assess response to therapy or development of therapeutic resistance.
Hyperpolarized (HP) 13C MRI is a paradigm shifting new MR molecular imaging technique that provides new
measures to detect, characterize aggressiveness, and monitor therapy in order to improve cancer clinical trials
and individualized patient care. The scientific premise for this project is that, with the success of phase 1
clinical trial of HP 13C-pyruvate imaging in prostate cancer patients, the proliferation of commercially available
clinical polarizers, and the strong pre-clinical data demonstrating the potential value of HP 13C urea & pyruvate
for advancing cancer imaging, the time is right for translating this new technology into the clinic and integrating
it into current state-of-the-art imaging approaches. This Academic-Industry partnership is critical for robustly
translating this novel imaging technology into the clinical arena, and UCSF and General Electric (GE) are
uniquely positioned to accomplish this goal together.
Although the novel hyperpolarized imaging tools and methods developed and disseminated in this academic-
industrial partnership will initially be applied to patients with prostate cancer, they will have general applicability
for a wide variety of cancers, and other human diseases.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
High Field MRI For Optimized Translational 1H Multiparametric and Multinuclear Imaging Research
-
批准号:10175910
-
项目类别:
-
资助金额:$200.0万
-
财政年份:2021
-
负责人:John Kurhanewicz
-
依托单位:
Preclinical imaging characterization and resource development of PDX SCNC prostate cancer murine models
-
批准号:10378320
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:John Kurhanewicz
-
依托单位:
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI
-
批准号:10669081
-
项目类别:
-
资助金额:$65.68万
-
财政年份:2020
-
负责人:John Kurhanewicz
-
依托单位:
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI
-
批准号:10057724
-
项目类别:
-
资助金额:$67.02万
-
财政年份:2020
-
负责人:John Kurhanewicz
-
依托单位:
Characterization of PDX SCNC prostate cancer metastatic murine models and development of associated research resources
-
批准号:10533469
-
项目类别:
-
资助金额:$7.59万
-
财政年份:2020
-
负责人:John Kurhanewicz
-
依托单位:
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI
-
批准号:10470345
-
项目类别:
-
资助金额:$65.68万
-
财政年份:2020
-
负责人:John Kurhanewicz
-
依托单位:
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI
-
批准号:10256057
-
项目类别:
-
资助金额:$67.02万
-
财政年份:2020
-
负责人:John Kurhanewicz
-
依托单位:
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI
-
批准号:10737795
-
项目类别:
-
资助金额:$7.44万
-
财政年份:2020
-
负责人:John Kurhanewicz
-
依托单位:
Metabolic imaging comparisons of patient-derived models of renal cell carcinoma
-
批准号:9753176
-
项目类别:
-
资助金额:$62.63万
-
财政年份:2017
-
负责人:John Kurhanewicz
-
依托单位:
Metabolic imaging comparisons of patient-derived models of renal cell carcinoma
-
批准号:10227078
-
项目类别:
-
资助金额:$63.36万
-
财政年份:2017
-
负责人:John Kurhanewicz
-
依托单位:
Development and Translation of Hyperpolarized C-13 Prostate Cancer MRI Methods
-
批准号:8573124
-
项目类别:
-
资助金额:$119.1万
-
财政年份:2013
-
负责人:John Kurhanewicz
-
依托单位:
Development and Translation of Hyperpolarized C-13 Prostate Cancer MRI Methods
-
批准号:9107862
-
项目类别:
-
资助金额:$118.54万
-
财政年份:2013
-
负责人:John Kurhanewicz
-
依托单位:
Development and Translation of Hyperpolarized C-13 Prostate Cancer MRI Methods
-
批准号:8713993
-
项目类别:
-
资助金额:$114.78万
-
财政年份:2013
-
负责人:John Kurhanewicz
-
依托单位:
New Instrumentation and Techniques for Hyperpolarized Metabolic and Perfusion MRI
-
批准号:9058042
-
项目类别:
-
资助金额:$71.29万
-
财政年份:2013
-
负责人:John Kurhanewicz
-
依托单位:
Development and Translation of Hyperpolarized C-13 Prostate Cancer MRI Methods
-
批准号:8891426
-
项目类别:
-
资助金额:$116.26万
-
财政年份:2013
-
负责人:John Kurhanewicz
-
依托单位:
New Instrumentation and Techniques for Hyperpolarized Metabolic and Perfusion MRI
-
批准号:8585007
-
项目类别:
-
资助金额:$70.44万
-
财政年份:2013
-
负责人:John Kurhanewicz
-
依托单位:
PET and MR-Compatible Bioreactor for Cross-Platform Biomarker Development
-
批准号:8520274
-
项目类别:
-
资助金额:$15.32万
-
财政年份:2012
-
负责人:John Kurhanewicz
-
依托单位:
Novel Hyperpolarized MR Markers of Advanced Prostate Cancer Therapy
-
批准号:8551645
-
项目类别:
-
资助金额:$56.37万
-
财政年份:2012
-
负责人:John Kurhanewicz
-
依托单位:
PET and MR-Compatible Bioreactor for Cross-Platform Biomarker Development
-
批准号:8401876
-
项目类别:
-
资助金额:$13.55万
-
财政年份:2012
-
负责人:John Kurhanewicz
-
依托单位:
Novel Hyperpolarized MR Markers of Advanced Prostate Cancer Therapy
-
批准号:8698716
-
项目类别:
-
资助金额:$58.33万
-
财政年份:2012
-
负责人:John Kurhanewicz
-
依托单位:
海外基金